CoChat
Sign Up
Cited by 1,080

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Tuberous Sclerosis Complex Gene Products, Tuberin and Hamartin, Control mTOR Signaling by Acting as a GTPase-Activating Protein Complex toward Rheb

Tee, Andrew R, Manning, Brendan D, Roux, Philippe P, Cantley, Lewis C, Blenis, John·2003·Current Biology
DOI 10.1016/s0960-9822(03)00506-2
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0960-9822(03)00506-2

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 3 references

Research works printed but not linked: 46

  1. Cheadle, 2000, Molecular genetic advances in tuberous sclerosis, Hum. Genet., 107, 97, 10.1007/s004390000348 · DOI
  2. Carbonara, 1994, 9q34 loss of heterozygosity in a tuberous sclerosis astrocytoma suggests a growth suppressor-like activity also for the TSC1 gene, Hum. Mol. Genet., 3, 1829, 10.1093/hmg/3.10.1829 · DOI
  3. Green, 1994, Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients, Nat. Genet., 6, 193, 10.1038/ng0294-193 · DOI
  4. Green, 1994, The tuberous sclerosis gene on chromosome 9q34 acts as a growth suppressor, Hum. Mol. Genet., 3, 1833, 10.1093/hmg/3.10.1833 · DOI
  5. Ito, 1999, Gigas, a Drosophila homolog of tuberous sclerosis gene product-2, regulates the cell cycle, Cell, 96, 529, 10.1016/S0092-8674(00)80657-1 · DOI
  6. Onda, 1999, Tsc2(+/−) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background, J. Clin. Invest., 104, 687, 10.1172/JCI7319 · DOI · Paper page
  7. van Slegtenhorst, 1997, Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34, Science, 277, 805, 10.1126/science.277.5327.805 · DOI · Paper page
  8. van Slegtenhorst, 1998, Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products, Hum. Mol. Genet., 7, 1053, 10.1093/hmg/7.6.1053 · DOI · Paper page
  9. Lamb, 2000, The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho, Nat. Cell Biol., 2, 281, 10.1038/35010550 · DOI
  10. Wienecke, 1995, Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific Rap1GAP activity, J. Biol. Chem., 270, 16409, 10.1074/jbc.270.27.16409 · DOI
  11. Xiao, 1997, The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis, J. Biol. Chem., 272, 6097, 10.1074/jbc.272.10.6097 · DOI
  12. Astrinidis, 2002, Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration, Oncogene, 21, 8470, 10.1038/sj.onc.1205962 · DOI
  13. Potter, 2001, Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size, Cell, 105, 357, 10.1016/S0092-8674(01)00333-6 · DOI
  14. Gao, 2001, TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth, Genes Dev., 15, 1383, 10.1101/gad.901101 · DOI
  15. Zhang, 2000, Regulation of cellular growth by the Drosophila target of rapamycin dTOR, Genes Dev., 14, 2712, 10.1101/gad.835000 · DOI
  16. Manning, 2002, Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway, Mol. Cell, 10, 151, 10.1016/S1097-2765(02)00568-3 · DOI · Paper page
  17. Inoki, 2002, TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling, Nat. Cell Biol., 4, 648, 10.1038/ncb839 · DOI · Paper page
  18. Gao, 2002, Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling, Nat. Cell Biol., 4, 699, 10.1038/ncb847 · DOI
  19. Fingar, 2002, Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E, Genes Dev., 16, 1472, 10.1101/gad.995802 · DOI · Paper page
  20. Beugnet, 2003, Regulation of targets of mTOR (mammalian target of rapamycin) signalling by intracellular amino acid availability, Biochem. J., 372, 555, 10.1042/bj20021266 · DOI · Paper page
  21. Niida, 1999, Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis, Hum. Mutat., 14, 412, 10.1002/(SICI)1098-1004(199911)14:5<412::AID-HUMU7>3.0.CO;2-K · DOI
  22. Mach, 2000, Loss of Rhb1, a Rheb-related GTPase in fission yeast, causes growth arrest with a terminal phenotype similar to that caused by nitrogen starvation, Genetics, 155, 611, 10.1093/genetics/155.2.611 · DOI
  23. Urano, 2000, The Saccharomyces cerevisiae Rheb G-protein is involved in regulating canavanine resistance and arginine uptake, J. Biol. Chem., 275, 11198, 10.1074/jbc.275.15.11198 · DOI
  24. Yamagata, 1994, Rheb, a growth factor- and synaptic activity-regulated gene, encodes a novel Ras-related protein, J. Biol. Chem., 269, 16333, 10.1016/S0021-9258(17)34012-7 · DOI
  25. Im, 2002, Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells, Oncogene, 21, 6356, 10.1038/sj.onc.1205792 · DOI
  26. Chung, 1992, Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases, Cell, 69, 1227, 10.1016/0092-8674(92)90643-Q · DOI
  27. Martin, 2002, Coordinate regulation of translation by the PI 3-kinase and mTOR pathways, Adv. Cancer Res., 86, 1, 10.1016/S0065-230X(02)86001-8 · DOI
  28. Blenis, 1986, Stimulation of ribosomal protein S6 kinase activity by pp60v-src or by serum, Proc. Natl. Acad. Sci. USA, 83, 1733, 10.1073/pnas.83.6.1733 · DOI
  29. Schalm, 2002, Identification of a conserved motif required for mTOR signaling, Curr. Biol., 12, 632, 10.1016/S0960-9822(02)00762-5 · DOI
  30. Romanelli, 2002, Characterization of phosphatidylinositol 3-kinase-dependent phosphorylation of the hydrophobic motif site Thr(389) in p70 S6 kinase 1, J. Biol. Chem., 277, 40281, 10.1074/jbc.M205168200 · DOI
  31. Yang, 2001, Failure to farnesylate Rheb protein contributes to the enrichment of G0/G1 phase cells in the Schizosaccharomyces pombe farnesyltransferase mutant, Mol. Microbiol., 41, 1339, 10.1046/j.1365-2958.2001.02599.x · DOI
  32. Wittinghofer, 1995, Ras-effector interactions, the problem of specificity, FEBS Lett., 369, 52, 10.1016/0014-5793(95)00667-X · DOI
  33. Proud, 2001, Interplay between insulin and nutrients in the regulation of translation factors, Biochem. Soc. Trans., 29, 541, 10.1042/bst0290541 · DOI
  34. Stocker, 2003, Rheb is an essential regulator of S6K in controlling cell growth in Drosophila, Nat. Cell Biol., 5, 559, 10.1038/ncb995 · DOI
  35. Saucedo, 2003, Rheb promotes cell growth as a component of the insulin/TOR signalling network, Nat. Cell Biol., 5, 566, 10.1038/ncb996 · DOI
  36. Zhang, 2003, Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins, Nat. Cell Biol., 5, 578, 10.1038/ncb999 · DOI
  37. Hancock, 1989, All ras proteins are polyisoprenylated but only some are palmitoylated, Cell, 57, 1167, 10.1016/0092-8674(89)90054-8 · DOI
  38. Plank, 1998, Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles, Cancer Res., 58, 4766
  39. Sabatini, 1999, Interaction of RAFT1 with gephyrin required for rapamycin-sensitive signaling, Science, 284, 1161, 10.1126/science.284.5417.1161 · DOI
  40. Chipperfield, 1985, Activation of Ha-ras p21 by substitution, deletion, and insertion mutations, Mol. Cell. Biol., 5, 1809
  41. Niida, 2001, Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions, Am. J. Hum. Genet., 69, 493, 10.1086/321972 · DOI
  42. Richards, 2001, Characterization of regulatory events associated with membrane targeting of p90 ribosomal S6 kinase 1, Mol. Cell. Biol., 21, 7470, 10.1128/MCB.21.21.7470-7480.2001 · DOI
  43. Richards, 1999, Ribosomal S6 kinase 1 (RSK1) activation requires signals dependent on and independent of the MAP kinase ERK, Curr. Biol., 9, 810, 10.1016/S0960-9822(99)80364-9 · DOI
  44. Martin, 2001, Regulation of ribosomal S6 kinase 2 by effectors of the phosphoinositide 3-kinase pathway, J. Biol. Chem., 276, 7884, 10.1074/jbc.M006969200 · DOI
  45. Shimamura, 2000, Rsk1 mediates a MEK-MAP kinase cell survival signal, Curr. Biol., 10, 127, 10.1016/S0960-9822(00)00310-9 · DOI
  46. Downward, 1995, Measurement of nucleotide exchange and hydrolysis activities in immunoprecipitates, 10.1016/S0076-6879(95)55013-5 · DOI

Cited by

Sorted by citations

See all 1,080

Metadata

Authors
Tee, A. R., Manning, B. D., Roux, P. P., Cantley, L. C., & Blenis, J.
Venue
Current Biology
Publisher
Elsevier BV
Published
2003-08
Volume
13
Issue
15
Pages
1259-1268
ISSN
0960-9822
DOI
10.1016/s0960-9822(03)00506-2
Cited by
1,080
References
3
Language
en
Update notices
erratum (2022-02-07)
Licence
Funders
  • American Cancer Society
  • European Molecular Biology Organization
  • Human Frontier Science Program
  • National Institutes of Health (CA46595, GM41890, GM51405, GM56203)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review